drugset / Trial / NCT01145885

BI 6727 (Volasertib) Human ADME Trial in Various Solid Tumours

NCT01145885

Phase 1 Completed 7 enrolled Boehringer Ingelheim
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Investigation of absorption, distribution, metabolism and excretion (ADME) and assessment of safety, tolerability and preliminary therapeutic effects of \[14C\]volasertib in patients with advanced solid tumours.

Timeline

Start
2010-06
Primary completion
2010-11
Completion
2010-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Volasertib Small molecule 300 mg Intravenous

Indications